[Follicular non-Hodgkin lymphomas and minimal residual disease].
Follicular lymphomas constitute 40% of non-Hodgkin lymphomas (NHL). Most of them (85%) present the t14:18 translocation with altered expression of BCL2. The lack of clinical prognostic factors able to separate a group of patients with poor outcome have shifted the interest to the assessment of t14:18 as a molecular marker for clinical response. Moreover, the translocation site is being studied as a prognostic variable. New therapeutic modalities aimed to affect BCL2 such as the antiidiotype vaccines or antisense oligonucleotides against BCL2 have motivated great expectancy.
Bruno
S
S
Departamento de Oncohematología, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, P. de Melo 3081, 1425 Buenos Aires, Argentina. salvador.bruno@mail.roche.com.ar
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000235:genetics; D020169:Caspases / Q000235:genetics; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000235:genetics*; D018365:Neoplasm, Residual / Q000235:genetics*; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D014178:Translocation, Genetic
D019253:Proto-Oncogene Proteins c-bcl-2; D020169:Caspases